Clinical Trials Directory

Trials / Completed

CompletedNCT02998255

Effect of Single Dose of 2L PEG on Bowel Preparation in Average-risk Patients Undergoing Colonoscopy

Effect of Single Dose of 2L PEG on Bowel Preparation in Average-risk Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
940 (actual)
Sponsor
Air Force Military Medical University, China · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Adequate quality of bowel preparation(BP) is important for colonoscopy. Several guidelines recommend that split-dose of 4L PEG should be used as a standard regime for BP. However, the high-volume PEG still results in lower compliance to the regime and increased cost. Some high risk factors for inadequate BP have been identified, including old age, constipation, diabetes, the use of narcotics and prior history of inadequate BP. For average-risk patients without the high risk factors, the procedure of BP could be easier. In the previous study, with the use of single dose of 2L PEG, more than 90% of average-risk patients achieved adequate BP. Here investigators hypothesized that compared with the standard split dose of 4L PEG, single dose of 2L PEG may be not inferior in BP quality while may be accompanied with better tolerability.

Conditions

Interventions

TypeNameDescription
DRUGSingle dose of 2L PEGPatients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
DRUGSplit dose of 4L PEGAll patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.

Timeline

Start date
2016-12-01
Primary completion
2017-08-01
Completion
2017-08-01
First posted
2016-12-20
Last updated
2017-09-13

Locations

3 sites across 1 country: China

Source: ClinicalTrials.gov record NCT02998255. Inclusion in this directory is not an endorsement.